Skip to main
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 28%
Sell 6%
Strong Sell 6%

Bulls say

Doximity Inc. has demonstrated impressive growth potential, particularly with its point-of-care (POC) and formulary offerings, which experienced over 100% growth during the recent buying season. The company's shares have shown resilience and a positive trend, increasing by 3.2% since September 8, indicating investor confidence in its performance and future prospects. Additionally, the company’s second-quarter guidance appears not only achievable but also presents opportunities for upward revision, supported by enhanced visibility and upfront buying from expanded service offerings.

Bears say

Doximity faces a negative outlook primarily due to downward guidance revisions from its pharmaceutical clients, driven by an uncertain economic environment that suggests a potential decline in revenue for fiscal years 2023 and 2024. Furthermore, the company’s stock appears expensive relative to its software peers, which raises concerns about its valuation amid high investor expectations. The potential for volatility in share prices is significant, particularly if Doximity fails to meet projected financial results or provide upward guidance, which could lead to investor disappointment.

Doximity (DOCS) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 28% suggest Holding, 6% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Buy based on their latest research and market trends.

According to 18 analysts, Doximity (DOCS) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.